Feline Osteoarthritis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class, (Nutraceuticals, Pharmaceuticals) By Formulation Type, (Oral tablets, Oral gels) By Distribution Channel, (Veterinary pharmacies, Retail pharmacies, Online pharmacies), and Region Forecast 2020-2031

Feline Osteoarthritis Treatment Market size was valued at US$ 3.7 billion in 2024 and is expected to reach US$ 5.2 billion by 2031, growing at a significant CAGR of 5.0% from 2025-2031. Feline osteoarthritis, often simply referred to as arthritis in cats, is a common degenerative joint disease that affects the joints and cartilage in a cat's body. This condition is relatively common in older cats but can also occur in younger ones due to factors like genetics, injury, or infection. Feline osteoarthritis treatment aims to manage pain and improve the cat's quality of life. The rising feline population plays a pivotal role in driving the market. With the global increase in the pet cat population, cases of feline osteoarthritis have risen, resulting in a higher demand for effective treatments like medication and therapy. As pet owners become more proactive in seeking solutions to improve the quality of life for their feline companions, the market experiences steady growth in response to this rising demographic trend.

Moreover, the aging feline population is a significant driver behind the growth of the market. As cats age, they become more susceptible to osteoarthritis, a degenerative joint disease that causes pain and mobility issues. With many cat owners considering their pets as part of the family, there is a growing emphasis on providing them with a comfortable and pain-free life in their senior years. This has led to increased awareness and diagnosis of feline osteoarthritis cases, driving the demand for effective treatment options.

However, stringent regulatory policies for the approval of veterinary medicines, complexity in early-stage disease diagnosis, less number of treatment options in the market, and lack of awareness about the disease in rural areas are the factors restraining the growth of the feline osteoarthritis management market. Meanwhile, ongoing clinical trials for feline osteoarthritis treatment create significant opportunities for growth. Key market players are developing innovative treatment solutions that further contribute to the market’s growth. For instance, in January 2022, Zoetis announced the approval of the first and only injectable monoclonal antibody (mAb), Solensia by the FDA to control osteoarthritis pain in cats.

Key Developments

In October 2021, Scout Bio initiated Multi-Center Clinical Study of company’s one-time AAV gene therapy, SB-007, for chronic arthritis pain in cats.